

The ResQPOD, or an earlier version of the impedance threshold device (ITD), has been the subject of over 65 published clinical trials, animal studies and review articles. Based upon the multiple positive human and animal studies, the 2005 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care gave an ITD (e.g. ResQPOD) a Class IIa recommendation.<sup>45</sup> The AHA recommendation means that there is strong evidence to demonstrate that the ResQPOD enhances circulation, improves hemodynamics and increases the likelihood of resuscitation in patients in cardiac arrest. This level of AHA recommendation is higher than any other device or drug (e.g. epinephrine, vasopressin, amiodarone) used in the treatment of patients in cardiac arrest. Since 2005, more than 20 additional articles and studies have been published in support of that recommendation (bibliography on other side).

## HUMAN CLINICAL TRIALS

The ResQPOD has been evaluated in 15 human clinical trials during both

Conventional, standard manual CPR:

1,2,3,46,52,53,57,63,65,66,67; and in

Active compression decompression (ACD) CPR:

4,5,6,7,57.

These studies have shown that the ResQPOD:

- ♥ **Improves hemodynamics**
  - ◆ Systolic BP during cardiac arrest nearly doubled (2)
  - ◆ Mean coronary perfusion pressure improved by 70% (5)
- ♥ **Improves short and/or long-term survival from prehospital cardiac arrest:**
  - ◆ Survival to ED admission improved by 50% (3)
  - ◆ Survival to 24 hours in PEA patients more than doubled (1)
  - ◆ Survival to 24 hours in all patients improved 45 - 68% (4,6)
  - ◆ ROSC rates improved 31 - 80% (5, 46)
  - ◆ Survival to hospital discharge improved 80 - 98% (52,65)
  - ◆ Meta-analysis shows a more than doubling of favorable neurologic outcomes (57)
- ♥ **Improves short and/or long-term survival from in-hospital cardiac arrest:**
  - ◆ Survival to hospital discharge rates improved 62-73% with adoption of AHA guidelines (including ITD) (53,67)
- ♥ **Provides benefit in non-V-fib cardiac arrest rhythms:**
  - ◆ Survival to 24 hours in PEA patients more than doubled (1)
  - ◆ Survival in patients presenting in asystole tripled (3)
- ♥ **Works effectively on a variety of airway adjuncts (7)**
- ♥ **Is clinically and cost effective (66)**

## ANIMAL STUDIES

The ResQPOD has been evaluated in 19 animal studies during both:

Conventional, standard manual CPR:

16,17,18,19,20,23,43,49,50,55,63,64; and in

Active compression decompression (ACD) CPR:

8,9,11,12,13,20,23,44,47,49.

These studies have shown that the ResQPOD:

- ♥ **Improves hemodynamics and vital organ blood flow (8,9,11,12,16,17,18,19,20,43,44,47,49,55,63,64)**
  - ◆ **Increases cardiac output (43), coronary perfusion pressure (9,11,12,18,19,43,44,47,49,63) and blood flow to the heart (17,18,12 & 20 [doubles])**
  - ◆ **Increases cerebral perfusion pressure (43,47,49,50,63) and blood flow to the brain (11,18,12 & 17 [≥50%],43,47,50,55,63)**
  - ◆ **Raises aortic blood pressure (8,9,11,12,16,19,49)**
  - ◆ **Lowers intracranial pressure during decompression phase of CPR (50,63)**
- ♥ **Improves survival (9,16,44,64) and neurologically intact survival (16,47)**
- ♥ **Improves cerebral metabolism (8) and hemodynamics (8,11) during hypothermic cardiac arrest, and induces cerebral hypothermia more rapidly after ROSC (44)**
- ♥ **Increases the likelihood of successful defibrillation (9) or the total energy required for successful defibrillation (44,64)**
- ♥ **Circulates drugs more effectively (11)**
- ♥ **Improves hemodynamics in a pediatric model of cardiac arrest (50,63)**
- ♥ **Optimizes and compliments current AHA CPR recommendations (43,55)**

Finally, the best outcomes following cardiac arrest will be achieved with a continuum of care and therapies, not a single drug or device.<sup>48</sup> Advanced Circulatory Systems supports the approach taken by the Take Heart America™ Demonstration Project ([www.takeheartameria.org](http://www.takeheartameria.org)), which promotes a full spectrum of optimal therapies including public recognition, widespread bystander CPR, performance of high-quality CPR with an ITD, and definitive care at Level One Cardiac Arrest Centers<sup>66,67</sup> offering state-of-the-art post-resuscitation care to optimize neurologic recovery (e.g. therapeutic hypothermia).



# IMPEDANCE THRESHOLD DEVICE BIBLIOGRAPHY

1. **Aufderheide TP** et al. Clinical evaluation of an inspiratory ITD during standard CPR in patients with out-of-hospital cardiac arrest. *Crit Care Med* 2005;33(4):734-40.
2. **Pirrallo RG** et al. Effect of an inspiratory ITD on hemodynamics during conventional manual CPR. *Resus* 2005;66:13-20.
3. **Thayne RC** et al. Use of an ITD improves short-term outcomes following out-of-hospital cardiac arrest. *Resus* 2005;67(1):103-08.
4. **Wolcke BB** et al. Comparison of standard CPR versus the combination of ACD CPR and an inspiratory ITD for out-of-hospital cardiac arrest. *Circ* 2003;108(18):2201-5.
5. **Plaisance P** et al. Inspiratory impedance during ACD CPR: a randomized evaluation in patients in cardiac arrest. *Circ* 2000;101(9):989-94.
6. **Plaisance P** et al. Evaluation of an ITD in patients receiving ACD CPR for out of hospital cardiac arrest. *Resus* 2004;61(3):265-71.
7. **Plaisance P** et al. Use of an inspiratory ITD on a facemask and ET tube to reduce intrathoracic pressures during the decompression phase of ACD CPR. *Crit Care Med* 2005;33(5):990-4.
8. **Bahlmann L** et al. Brain metabolism during CPR assessed with microdialysis. *Resus* 2003;59(2):255-60.
9. **Lurie KG** et al. Improving ACD CPR with an inspiratory impedance valve. *Circ* 1995;91(6):1629-32.
10. **Lurie K** et al. Improving the efficiency of CPR with an inspiratory ITV. *Crit Care Med* 2000;28(11 - Suppl):N207-9.
11. **Raedler C** et al. Vasopressor response in a porcine model of hypothermic cardiac arrest is improved with ACD CPR using the inspiratory ITV. *Anesth Analg* 2002;95(6):1496-502.
12. **Voelckel WG** et al. Effects of ACD CPR with the ITV in a young porcine model of cardiac arrest. *Pediatr Res* 2002;51(4):523-7.
13. **Voelckel WG** et al. The effects of PEEP during ACD CPR with the ITV. *Anesth Analg* 2001;92(4):967-74.
14. **Sigurdsson G** et al. Cardiorespiratory interactions and blood flow generation during cardiac arrest and other states of low blood flow. *Curr Opin Crit Care* 2003;9(3):183-8.
15. **Frascone RJ** et al. Combination of ACD CPR and the inspiratory ITD: state of the art. *Curr Opin Crit Care* 2004;10(3):193-201.
16. **Lurie KG** et al. Use of an inspiratory impedance valve improves neurologically intact survival in a porcine model of ventricular fibrillation. *Circ* 2002;105(1):124-9.
17. **Lurie KG** et al. Optimizing standard CPR with an inspiratory ITV. *Chest* 1998;113(4):1084-90.
18. **Lurie KG** et al. Improving standard CPR with an inspiratory ITV in a porcine model of cardiac arrest. *Anesth Analg* 2001;93(3):649-55.
19. **Yannopoulos D** et al. Reducing ventilation frequency combined with an inspiratory impedance device improves CPR efficiency in a swine model of cardiac arrest. *Resus* 2004;61(1):75-82.
20. **Langhelle A** et al. Inspiratory ITV during CPR. *Resus* 2002;52(1):39-48.
21. **Lurie KG** et al. Augmentation of ventricular preload during treatment of cardiovascular collapse and cardiac arrest. *Crit Care Med* 2002;30(4):S162-5.
22. **Lurie KG** et al. Evaluation of a prototypic inspiratory ITV designed to enhance the efficiency of CPR. *Resp Care* 2003;48(1):52-57.
23. **Lurie KG** et al. Potential role of the vocal cords during CPR. *Circ* 1998;98(17):1-478.
24. **Gabrielli A** et al. Alternative ventilation strategies in CPR. *Curr Opin Crit Care* 2002;8(3):199-211.
25. **Genzwuerker HV** et al. Influence of the ITV on ventilation with different airway devices. Abstract presented at ESA (Lisbon, Portugal; June 2004).
26. **Babbs CF**. Circulatory adjuncts. Newer methods of CPR. *Cardiol Clin* 2002;20(1):37-59.
27. **Lindner KH** et al. New mechanical methods for CPR. Literature study and analysis of effectiveness. *Anaesthesist* 1997;46(3):220-30.
28. **Lurie K**. Mechanical devices for CPR: an update. *Emerg Med Clin North Am* 2002;20(4):771-84.
29. **Lurie KG**. Recent advances in mechanical methods of CPR. *Acta Anaesthesiol Scand Suppl.* 1997;111:49-52.
30. **Lurie K**. Bringing back the nearly dead. The hope and the challenge. *Minn Med* 2002;85(4):39-42.
31. **Lurie KG** et al. Recent advances in CPR. *J Card Electro* 1997;8(5):584-600.
32. **Lurie K** et al. Mechanical advances in CPR. *Curr Opin Crit Care* 2001;7(3):170-5.
33. **Lurie K** et al. Recent advances in mechanical CPR devices. *Curr Opin Crit Care.* 1999;5(3):184-192.
34. **Lurie K** et al. Use of an inspiratory ITV during CPR: a progress report. *Resus* 2000;44(3):219-30.
35. **Mauer D** et al. Alternative methods of mechanical CPR. *Resus* 2000;44(2):81-95.
36. **Sugiyama A** et al. Utilization of a model lung system to assess the effects of an inspiratory ITV on the relationship between active decompression and intrathoracic pressure. *Resus* 1999;42(3):231-4.
37. **Sukhum P** et al. Recent advances in ACD CPR. *Baillière's Clinical Anaesthesiology* 2000;14(3):483-496.
38. **Wenzel V** et al. The new international guidelines for CPR: an analysis and comments on the most important changes. *Anaesthesist* 2001;50(5):342-57.
39. **Smith T**. Alternative CPR devices. *Curr Opin Crit Care* 2002;8(3):219-23.
40. **Wigginton JG** et al. Mechanical devices for CPR. *Curr Opin Crit Care* 2005;11(3):219-23.
41. **Wigginton JG**. The inspiratory ITD for treatment of patients in cardiac arrest. *Bus Briefing: Long-term Healthcare* 2005 and *Bus Briefing: Emerg Med Rev* 2005:58-61.
42. **Wesley K**. Let it flow: ResQPOD Circulatory Enhancer enables more effective CPR. *JEMS* 2005;30(12):72-74.
43. **Yannopoulos D** et al. Clinical and hemodynamic comparison of 15:2 and 30:2 compression-to-ventilation ratios for CPR. *Crit Care Med* 2006;34(5):1444-9.
44. **Srinivasan V** et al. Rapid induction of cerebral hypothermia is enhanced with ACD plus inspiratory ITD CPR in a porcine model of cardiac arrest. *J Am Coll Cardiol* 2006;47(4):835-41.
45. **2005 American Heart Association Guidelines for CPR and Emergency Cardiac Care**; Part 6: CPR techniques and devices. *Circ* 2005;112:IV-48.
46. **Vartanian L** et al. Use of an ITD improves survival in a suburban EMS system. *Circ* 2006;114(18):II-1209.
47. **Metzger AK** et al. Effect of an ITD and a novel ACD CPR device on cerebral perfusion pressures and 24-hour survival in a porcine model of cardiac arrest. *Circ* 2006;114(18):II-554.
48. **Yannopoulos D** et al. Acute management of sudden cardiac death in adults based upon the new CPR guidelines. *Europace* 2007;9:2-9.
49. **Yannopoulos D** et al. Lower extremity counterpulsation during the decompression phase of CPR improves hemodynamics and provides continuous forward carotid blood flow. *Circ* 2007;Supplement II;116(16):II-485.
50. **Alexander C** et al. Dual mechanism of blood flow augmentation to the brain using an ITD in a pediatric model of cardiac arrest. *Circ* 2007;Supplement II;116(16):II-433.
51. **Aufderheide T** et al. Resuscitation in 2005: New ways to optimize manual CPR. *EMS Mag* 2005;34(9):42-45.
52. **Aufderheide TP** et al. A tale of seven EMS systems: an ITD and improved CPR techniques double survival rates after out-of-hospital cardiac arrest. *Circ* 2007;Suppl II;116(16):II-936.
53. **Thigpen K** et al. Implementation of the 2005 CPR guidelines and use of an ITD improve survival from in-hospital cardiac arrest. *Ann Emerg Med* 2008;51(4):475.
54. **Babbs CF**. Effects of an ITV upon hemodynamics in standard CPR: studies in a refined computational model. *Resus* 2005;66(3):335-45.
55. **Lurie KG** et al. Comparison of a 10 breaths/min vs 2 breaths/min strategy during CPR in a porcine model of cardiac arrest. *Resp Care* 2008;52(7):862-870.
56. **Aufderheide TP** et al. Vital organ blood flow with the ITD. *Crit Care Med* 2006;34(12):S466-73.
57. **Cabrini L** et al. Impact of ITDs on CPR: a systematic review and meta-analysis of randomized controlled studies. *Crit Care Med* 2008;36(5):1625-1632.
58. **Wesley K**. Keep on Pump'n. *EMS Professionals*; Sept-Oct 2005:40.
59. **Aufderheide TP** et al. Resuscitation Outcomes Consortium (ROC) PRIMED cardiac arrest trial methods part 1: rationale and methodology for the ITD protocol. *Resus* 2008;78:179-185.
60. **Yannopoulos D** et al. Chapter 3.8: CPR: guidelines and advancements for victims of cardiac arrest. *Cardiac Pacing and Defibrillation – Principle and Practice* (textbook).
61. **Pilvinis V** et al. Physiological aspects of CPR in adults. *Medicina (Kaunas)* 2006;42(4):346-53.
62. **Pirracchio R** et al. The ITV for CPR: a review of the literature. *Curr Opin Crit Care* 2007;13(3):280-6.
63. **Aufderheide TP** et al. From laboratory science to six EMS systems: new understanding of the physiology of CPR increases survival rates after cardiac arrest. *Crit Care Med* 2008;36(11):S397-S404.
64. **Matsuura T** et al. An ITD combined with ACD CPR device (LUCAS) improves the chances for survival in pigs in cardiac arrest. *Circ* 2008;118:S1449-50.
65. **Lurie K** et al. Take Heart America™: a community-based sudden cardiac arrest survival initiative is saving lives by implementing the most highly recommended 2005 AHA resuscitation guidelines. *Circ* 2008;118:S1464.
66. **Lurie K** et al. Level One Cardiac Arrest Centers are clinically and cost effective. *Circ* 2008;118:S1486.
67. **Davis S** et al. Implementation of the 2005 AHA guidelines together with the ITD improves hospital discharge rates after in-hospital cardiac arrest. *Circ* 2008;118:S765.



ADVANCED CIRCULATORY SYSTEMS, INC.

[www.advancedcirculatory.com](http://www.advancedcirculatory.com)  
1-877-ResQPOD (737-7763)

The generally cleared indication for the ResQPOD is for a temporary increase in blood circulation during emergency care, hospital, clinic and home use. Studies are on-going in the United States to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest. The studies listed here are not intended to imply specific outcome-based claims not yet cleared by the US Food and Drug Administration.